Detail

Basic Information Clinical Results Relationship Graph

Basic Information

Gene symbol	CD19	Synonyms	B4, CVID3	Type of gene	protein-coding
Chromosome	16	Map location	16p11.2	dbXrefs
Description	CD19 molecule

GTO ID	GTC0360
Trial ID	NCT03068416
Disease	B-Cell Lymphoma \| B-Cell Leukemia
Altered gene	CD19
Therapeutic/Target gene	Target gene
Therapy	CAR-T cell
Treatment	CD19 CAR-T cells
Generation	3rd
Phase	Phase2
Recruitment status	Completed
Title	CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy
Year	2017
Country	Sweden
Company sponsor	Uppsala University
Other ID(s)	004:TCELL\|2016-004043-36

Vector information

Vector	retrovirus
Construct	scFv-CD28-4-1BB-CD3ζ
Transgene/Inserted gene	CD19 targeting antibody scFv; signaling domains derived from CD3 zeta, CD28 and 4-1BB
Vector production method	The retroviral vector were produced at the Center for Cell and Gene Therapy at Baylor College of Medicine (Houston, TX), encoding for CAR SFG αCD19.28.4-1BB-ζ (19) in retronectin (TaKaRa/Clonetech)-coated plates.

Clinical Result

Cohort 1

Administration route	intravenous infusion
Dosage	2E8 cells/m^2
Donor type	Autologous
Pts	24
Age	Child, Adult, Older_Adult
Lymph depletion	Yes
Outcome	6/24(CR); 3/24(PR); 6/24(SD); 9/24(PD) at 1 month. The median progression-free survival (PFS) was 105 days (21-1, 373+ days) and the median overall survival (OS) was 316 days (57-1, 413+ days)
Adverse reactions	4/24(cytokine release syndrome)
References	PMID: 37540566

Relationship Graph

Overview of Knowledge Graph